Education
About Us
Working with TipRanks
Follow Us
Quince Therapeutics (QNCX)
:QNCX
Total Valuation
Quince Therapeutics has a market cap or net worth of $198.78M. The enterprise value is $79.65M.
Market Cap$198.78M
Enterprise Value$79.65M
Share Statistics
Quince Therapeutics has 55,681,490 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding55,681,490
Owned by Insiders14.70%
Owned by Institutions9.26%
Financial Efficiency
Quince Therapeutics’s return on equity (ROE) is -1.89 and return on invested capital (ROIC) is -53.42%.
Return on Equity (ROE)-1.89
Return on Assets (ROA)-0.50
Return on Invested Capital (ROIC)-53.42%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee0.00
Profits Per Employee-1.58M
Employee Count36
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Quince Therapeutics is ―. Quince Therapeutics’s PEG ratio is -0.03.
PE Ratio―
PS Ratio0.00
PB Ratio2.68
Price to Fair Value2.68
Price to FCF-2.52
Price to Operating Cash Flow-2.86
PEG Ratio-0.03
Income Statement
In the last 12 months, Quince Therapeutics had revenue of 0.00 and earned -56.83M in profits. Earnings per share was -1.31.
Revenue0.00
Gross Profit0.00
Operating Income-57.28M
Pretax Income-56.74M
Net Income-56.83M
EBITDA-35.98M
Earnings Per Share (EPS)-1.31
Cash Flow
In the last 12 months, operating cash flow was -38.50M and capital expenditures -481.00K, giving a free cash flow of -38.98M billion.
Operating Cash Flow-38.50M
Free Cash Flow-38.98M
Free Cash Flow per Share-0.70
Dividends & Yields
Quince Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.02
52-Week Price Change102.84%
50-Day Moving Average2.48
200-Day Moving Average1.69
Relative Strength Index (RSI)57.53
Average Volume (3m)1.03M
Important Dates
Quince Therapeutics upcoming earnings date is Mar 3, 2026, After Close (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 3, 2026
Ex-Dividend Date―
Financial Position
Quince Therapeutics as a current ratio of 6.05, with Debt / Equity ratio of 148.06%
Current Ratio6.05
Quick Ratio6.05
Debt to Market Cap0.18
Net Debt to EBITDA-0.15
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Quince Therapeutics has paid 87.00K in taxes.
Income Tax87.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Quince Therapeutics EV to EBITDA ratio is -1.58, with an EV/FCF ratio of -2.78.
EV to Sales0.00
EV to EBITDA-1.58
EV to Free Cash Flow-2.78
EV to Operating Cash Flow-2.81
Balance Sheet
Quince Therapeutics has $26.29M in cash and marketable securities with $17.99M in debt, giving a net cash position of $8.29M billion.
Cash & Marketable Securities$26.29M
Total Debt$17.99M
Net Cash$8.29M
Net Cash Per Share$0.15
Tangible Book Value Per Share-$0.69
Margins
Gross margin is -41.07%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-41.07%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Quince Therapeutics is $7.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.25
Price Target Upside103.08% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast2.26%